Compare TTMI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | BMRN |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.0B |
| IPO Year | 2000 | 1999 |
| Metric | TTMI | BMRN |
|---|---|---|
| Price | $91.99 | $55.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | ★ $98.50 | $87.24 |
| AVG Volume (30 Days) | 1.5M | ★ 2.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 211.11 | N/A |
| EPS | 1.68 | ★ 1.80 |
| Revenue | ★ $2,906,345,000.00 | $1,313,646,000.00 |
| Revenue This Year | $19.46 | $13.34 |
| Revenue Next Year | $17.05 | $11.42 |
| P/E Ratio | $56.87 | ★ $30.77 |
| Revenue Growth | ★ 18.98 | 17.62 |
| 52 Week Low | $16.55 | $50.76 |
| 52 Week High | $113.46 | $73.18 |
| Indicator | TTMI | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 33.85 |
| Support Level | $87.37 | $52.05 |
| Resistance Level | $110.38 | $56.89 |
| Average True Range (ATR) | 5.98 | 1.92 |
| MACD | -1.15 | -0.73 |
| Stochastic Oscillator | 12.99 | 10.89 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.